KMT Hepatech provides efficient and cost-effective in vivo research services utilizing platform technology of small animal model, the PXB-Mouse^®.

The PXB-Mouse^® is a chimeric mouse model with humanized liver with stable human hepatocytes engraftment of over 70 per cent.

In addition to in vivo services, KMT Hepatech will expand operations and start production of PXB-Cells^® – hepatocytes isolated from a PXB-Mouse^®liver.

Due to the expanding interest in the humanized liver mouse model across a wide range of drug development fields, the company now offers services in the following areas:

• Infectious diseases, such as Hepatitis C, Hepatitis B and Malaria
• Safety toxicity: early assessment of potential hepatotoxicity in in vivosettings prior to first-in-human studies
• Characterization of human-type drug and lipoprotein metabolism in in vivo settings prior to first-in-human studies

KMT Hepatech, Inc. owns an international patent portfolio that includes coverage of the uPA chimeric mouse model of HCV infection and on the uPA chimeric mouse for all potential applications including HBV, malaria and studies of toxicity, drug and lipoprotein metabolism.